Details of the Drug

General Information of Drug (ID: DM7I0MT)

Drug Name

MT203

Synonyms

Namilumab

Indication

Disease Entry	ICD 11	Status	REF
Plaque psoriasis	EA90.0	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Monoclonal antibody

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Granulocyte-macrophage colony-stimulating factor (CSF2)	TTNYZG2	CSF2_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Plaque psoriasis

ICD Disease Classification

EA90.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Granulocyte-macrophage colony-stimulating factor (CSF2)	DTT	CSF2	2.36E-01	-0.06	-0.26

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT02393378) Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate. U.S. National Institutes of Health.
2	GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential. Expert Rev Clin Immunol. 2015 Apr;11(4):457-65.